{"id":11142,"date":"2022-09-18T00:00:00","date_gmt":"2022-09-18T05:00:00","guid":{"rendered":"https:\/\/myeloma.ca\/1970\/01\/01\/le-belantamab-mafodotine-donne-un-bon-taux-de-reponse-dans-les-cas-de-myelome-multiple-recidivant-refractaire-en-anglais\/"},"modified":"2025-08-19T08:28:14","modified_gmt":"2025-08-19T13:28:14","slug":"le-belantamab-mafodotine-donne-un-bon-taux-de-reponse-dans-les-cas-de-myelome-multiple-recidivant-refractaire-en-anglais","status":"publish","type":"post","link":"https:\/\/myeloma.ca\/fr\/2022\/09\/18\/le-belantamab-mafodotine-donne-un-bon-taux-de-reponse-dans-les-cas-de-myelome-multiple-recidivant-refractaire-en-anglais\/","title":{"rendered":"LE B\u00c9LANTAMAB MAFODOTINE DONNE UN BON TAUX DE R\u00c9PONSE DANS LES CAS DE MY\u00c9LOME MULTIPLE R\u00c9CIDIVANT-R\u00c9FRACTAIRE (EN ANGLAIS)"},"content":{"rendered":"<p>Among patients with relapsed\/refractory multiple myeloma (RRMM), treatment with belantamab mafodotin appears to be a valid therapeutic option with potential clinical benefits, according to a real-world analysis presented at the 19th Annual Meeting and Exposition of the International Myeloma Society.<\/p>\n<p>Lire la suite <a href=\"https:\/\/www.hematologyadvisor.com\/home\/topics\/myeloma\/multiple-myeloma-belantamab-mafodotin-yields-good-response-rate-treatment\/?utm_source=newsletter&amp;utm_medium=email&amp;utm_campaign=NWLTR_HEM_UPDT_090822_RM&amp;hmEmail=t4mjb5pDq%2FT4EMHH1f6XPf%2FulL3aOOCE&amp;sha256email=f8197e3c3fe7c7a089d6a639a92231583494d8f5d9f107f3c8deff7a0952d05a&amp;hmSubId=&amp;NID=\" target=\"_blank\" rel=\"noopener\">ici<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Among patients with relapsed\/refractory multiple myeloma (RRMM), treatment with belantamab mafodotin appears to be a valid therapeutic option with potential clinical benefits, according to a real-world analysis presented at the 19th Annual Meeting and Exposition of the International Myeloma Society. Lire la suite ici.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[53,50,58,52],"tags":[],"class_list":["post-11142","post","type-post","status-publish","format-standard","hentry","category-actualites-et-evenement","category-news-events","category-nouvelles-de-myelome-canada","category-whats-new-at-myeloma-canada"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11142","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/comments?post=11142"}],"version-history":[{"count":1,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11142\/revisions"}],"predecessor-version":[{"id":31278,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11142\/revisions\/31278"}],"wp:attachment":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/media?parent=11142"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/categories?post=11142"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/tags?post=11142"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}